Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity

Cell signaling initiated at the epidermal growth factor receptor (EGFR), RAS oncoproteins, or PI3K contributes to a common pathway that promotes tumor survival after radiation-induced DNA damage. Inhibition of signaling at the level of EGFR, RAS, and PI3K has been tested, but clinical applicability...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer research (Chicago, Ill.) Vol. 68; no. 14; p. 5915
Main Authors:	Prevo, Remko, Deutsch, Eric, Sampson, Oliver, Diplexcito, Julie, Cengel, Keith, Harper, Jane, O'Neill, Peter, McKenna, W Gillies, Patel, Sonal, Bernhard, Eric J
Format:	Journal Article
Language:	English
Published:	United States 15.07.2008
Subjects:	Cell Cycle Cell Line, Tumor DNA Damage Drug Screening Assays, Antitumor Enzyme Inhibitors - pharmacology Flow Cytometry - methods Furans - pharmacology G2 Phase Histones - metabolism Humans Phosphoinositide-3 Kinase Inhibitors Phosphorylation Pyridines - pharmacology Pyrimidines - antagonists & inhibitors Pyrimidines - pharmacology Radiation Tolerance Radiation-Sensitizing Agents - pharmacology
ISSN:	1538-7445, 1538-7445
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Cell signaling initiated at the epidermal growth factor receptor (EGFR), RAS oncoproteins, or PI3K contributes to a common pathway that promotes tumor survival after radiation-induced DNA damage. Inhibition of signaling at the level of EGFR, RAS, and PI3K has been tested, but clinical applicability has been shown only at the level of the EGFR or by inhibiting RAS indirectly with prenyltransferase inhibitors. Inhibition of PI3K with LY294002 or wortmannin lacks specificity and has shown unacceptable toxicity in preclinical studies. We previously showed that inhibiting class I PI3K expression with siRNA resulted in enhanced radiation killing of tumor cells. Here, we tested the possibility of achieving specific tumor cell radiosensitization with a pharmacologic inhibitor of class I PI3K, the pyridinylfuranopyrimidine inhibitor PI-103. Our results show that inhibiting PI3K activity reduces phosphorylation of AKT at serine 473. Reduced survival is seen in cells with AKT activation and seems preferential for tumor cells over cells in which AKT activity is not elevated. Reduced survival is accompanied by persistence of DNA damage as evidenced by persistence of gamma H2AX and Rad 51 foci after irradiation in the presence of the inhibitor. Reduced survival does not result from cell cycle redistribution during the PI-103 treatment intervals tested, although combining PI-103 treatment with radiation enhances the G(2)-M delay observed after irradiation. These results indicate that pharmacologic inhibitors with enhanced specificity for class I PI3K may be of benefit when combined with radiotherapy.
AbstractList	Cell signaling initiated at the epidermal growth factor receptor (EGFR), RAS oncoproteins, or PI3K contributes to a common pathway that promotes tumor survival after radiation-induced DNA damage. Inhibition of signaling at the level of EGFR, RAS, and PI3K has been tested, but clinical applicability has been shown only at the level of the EGFR or by inhibiting RAS indirectly with prenyltransferase inhibitors. Inhibition of PI3K with LY294002 or wortmannin lacks specificity and has shown unacceptable toxicity in preclinical studies. We previously showed that inhibiting class I PI3K expression with siRNA resulted in enhanced radiation killing of tumor cells. Here, we tested the possibility of achieving specific tumor cell radiosensitization with a pharmacologic inhibitor of class I PI3K, the pyridinylfuranopyrimidine inhibitor PI-103. Our results show that inhibiting PI3K activity reduces phosphorylation of AKT at serine 473. Reduced survival is seen in cells with AKT activation and seems preferential for tumor cells over cells in which AKT activity is not elevated. Reduced survival is accompanied by persistence of DNA damage as evidenced by persistence of gamma H2AX and Rad 51 foci after irradiation in the presence of the inhibitor. Reduced survival does not result from cell cycle redistribution during the PI-103 treatment intervals tested, although combining PI-103 treatment with radiation enhances the G(2)-M delay observed after irradiation. These results indicate that pharmacologic inhibitors with enhanced specificity for class I PI3K may be of benefit when combined with radiotherapy. Cell signaling initiated at the epidermal growth factor receptor (EGFR), RAS oncoproteins, or PI3K contributes to a common pathway that promotes tumor survival after radiation-induced DNA damage. Inhibition of signaling at the level of EGFR, RAS, and PI3K has been tested, but clinical applicability has been shown only at the level of the EGFR or by inhibiting RAS indirectly with prenyltransferase inhibitors. Inhibition of PI3K with LY294002 or wortmannin lacks specificity and has shown unacceptable toxicity in preclinical studies. We previously showed that inhibiting class I PI3K expression with siRNA resulted in enhanced radiation killing of tumor cells. Here, we tested the possibility of achieving specific tumor cell radiosensitization with a pharmacologic inhibitor of class I PI3K, the pyridinylfuranopyrimidine inhibitor PI-103. Our results show that inhibiting PI3K activity reduces phosphorylation of AKT at serine 473. Reduced survival is seen in cells with AKT activation and seems preferential for tumor cells over cells in which AKT activity is not elevated. Reduced survival is accompanied by persistence of DNA damage as evidenced by persistence of gamma H2AX and Rad 51 foci after irradiation in the presence of the inhibitor. Reduced survival does not result from cell cycle redistribution during the PI-103 treatment intervals tested, although combining PI-103 treatment with radiation enhances the G(2)-M delay observed after irradiation. These results indicate that pharmacologic inhibitors with enhanced specificity for class I PI3K may be of benefit when combined with radiotherapy.Cell signaling initiated at the epidermal growth factor receptor (EGFR), RAS oncoproteins, or PI3K contributes to a common pathway that promotes tumor survival after radiation-induced DNA damage. Inhibition of signaling at the level of EGFR, RAS, and PI3K has been tested, but clinical applicability has been shown only at the level of the EGFR or by inhibiting RAS indirectly with prenyltransferase inhibitors. Inhibition of PI3K with LY294002 or wortmannin lacks specificity and has shown unacceptable toxicity in preclinical studies. We previously showed that inhibiting class I PI3K expression with siRNA resulted in enhanced radiation killing of tumor cells. Here, we tested the possibility of achieving specific tumor cell radiosensitization with a pharmacologic inhibitor of class I PI3K, the pyridinylfuranopyrimidine inhibitor PI-103. Our results show that inhibiting PI3K activity reduces phosphorylation of AKT at serine 473. Reduced survival is seen in cells with AKT activation and seems preferential for tumor cells over cells in which AKT activity is not elevated. Reduced survival is accompanied by persistence of DNA damage as evidenced by persistence of gamma H2AX and Rad 51 foci after irradiation in the presence of the inhibitor. Reduced survival does not result from cell cycle redistribution during the PI-103 treatment intervals tested, although combining PI-103 treatment with radiation enhances the G(2)-M delay observed after irradiation. These results indicate that pharmacologic inhibitors with enhanced specificity for class I PI3K may be of benefit when combined with radiotherapy.
Author	McKenna, W Gillies Diplexcito, Julie Cengel, Keith Sampson, Oliver Deutsch, Eric Patel, Sonal Prevo, Remko Harper, Jane O'Neill, Peter Bernhard, Eric J
Author_xml	– sequence: 1 givenname: Remko surname: Prevo fullname: Prevo, Remko organization: Radiobiology Research Institute, Oxford University, Oxford, United Kingdom – sequence: 2 givenname: Eric surname: Deutsch fullname: Deutsch, Eric – sequence: 3 givenname: Oliver surname: Sampson fullname: Sampson, Oliver – sequence: 4 givenname: Julie surname: Diplexcito fullname: Diplexcito, Julie – sequence: 5 givenname: Keith surname: Cengel fullname: Cengel, Keith – sequence: 6 givenname: Jane surname: Harper fullname: Harper, Jane – sequence: 7 givenname: Peter surname: O'Neill fullname: O'Neill, Peter – sequence: 8 givenname: W Gillies surname: McKenna fullname: McKenna, W Gillies – sequence: 9 givenname: Sonal surname: Patel fullname: Patel, Sonal – sequence: 10 givenname: Eric J surname: Bernhard fullname: Bernhard, Eric J
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/18632646$$D View this record in MEDLINE/PubMed
BookMark	eNpNUEtLxDAYDKK4D_0JSk7esubRJO1xKT4WFvWw95ImKRttk7Vphf57s7iKp2--YWZgZgHOffAWgBuCV4Tw_B5jnCOeSboq1y8oYSy5PANzwlmOZJbx8394BhYxvicLJ5hfghnJBaMiE3MQylbFCDfwbcPgh_MqWuj83tVucMHDeoLD3sLD1Dvj_NQ2Y698OL7dkfjThj4FIIIZtH6vvLYRDmOX2F4ZF6L1MeV9uWG6AheNaqO9Pt0l2D0-7MpntH192pTrLdJMFBJZlRGtjDAsp4VOFbSQDa5zqjNeU4qlbgQ1nBBsVV1IoTKWjFpJk2Zggi7B3U_soQ-fo41D1bmobdsqb8MYK1EwUuCCJ-HtSTjWnTXVITVT_VT9LkS_AaEWbAs
CitedBy_id	crossref_primary_10_1158_0008_5472_CAN_09_4040 crossref_primary_10_1016_j_bbrc_2013_01_038 crossref_primary_10_1016_j_ijrobp_2009_07_001 crossref_primary_10_1158_1078_0432_CCR_09_1324 crossref_primary_10_1172_JCI80402 crossref_primary_10_1097_JTO_0000000000000199 crossref_primary_10_1158_1535_7163_MCT_09_1001 crossref_primary_10_1155_2012_428565 crossref_primary_10_1016_j_radonc_2009_03_008 crossref_primary_10_1016_j_semradonc_2010_01_003 crossref_primary_10_1177_1533034615597366 crossref_primary_10_1517_13543770902967666 crossref_primary_10_1016_j_critrevonc_2015_07_005 crossref_primary_10_1016_j_ctrv_2010_03_010 crossref_primary_10_1093_ndt_gfp525 crossref_primary_10_1186_s13046_019_1419_1 crossref_primary_10_1093_jrr_rrt095 crossref_primary_10_1158_0008_5472_CAN_11_2263 crossref_primary_10_1007_s11626_018_0309_8 crossref_primary_10_1038_s41419_024_06755_x crossref_primary_10_1080_14728222_2017_1306055 crossref_primary_10_1038_cddis_2012_181 crossref_primary_10_1371_journal_pone_0038870 crossref_primary_10_4061_2011_762905 crossref_primary_10_3390_ph5111236 crossref_primary_10_1111_j_1750_3639_2008_00233_x crossref_primary_10_1016_j_semcancer_2015_07_003 crossref_primary_10_1016_j_canlet_2011_10_018 crossref_primary_10_15252_emmm_201606674 crossref_primary_10_3892_ol_2017_6208 crossref_primary_10_1016_j_pharmthera_2014_06_004 crossref_primary_10_1016_j_semradonc_2011_12_003 crossref_primary_10_1158_0008_5472_CAN_09_3901 crossref_primary_10_1369_0022155414523022 crossref_primary_10_3389_fphar_2016_00395 crossref_primary_10_1093_jrr_rrac018 crossref_primary_10_1097_IGC_0b013e3182021bfd crossref_primary_10_1158_1078_0432_CCR_15_2245 crossref_primary_10_3390_cancers12051278 crossref_primary_10_1007_s00280_012_2043_3 crossref_primary_10_1093_annonc_mdv105 crossref_primary_10_1016_j_ctro_2018_04_003 crossref_primary_10_1038_onc_2009_215 crossref_primary_10_1089_cbr_2012_1443 crossref_primary_10_4137_BCBCR_S13693 crossref_primary_10_1016_j_tranon_2014_02_012 crossref_primary_10_1158_0008_5472_CAN_16_2833 crossref_primary_10_1016_j_ijrobp_2014_12_039 crossref_primary_10_1016_j_semradonc_2016_05_004 crossref_primary_10_1016_j_bbrc_2014_04_147 crossref_primary_10_1007_s11060_010_0297_3 crossref_primary_10_1016_j_radonc_2013_05_012 crossref_primary_10_1158_0008_5472_CAN_09_3615 crossref_primary_10_1158_1541_7786_MCR_11_0312 crossref_primary_10_1016_j_ijrobp_2018_03_032 crossref_primary_10_1158_1541_7786_MCR_11_0592 crossref_primary_10_2353_ajpath_2009_081000 crossref_primary_10_1007_s11060_011_0679_1 crossref_primary_10_1007_s00432_014_1594_6 crossref_primary_10_1186_s12885_019_5307_z crossref_primary_10_1124_mol_112_080408 crossref_primary_10_1186_1476_4598_9_85 crossref_primary_10_1016_j_ctrv_2022_102417 crossref_primary_10_1038_aps_2013_22 crossref_primary_10_1155_2013_685308 crossref_primary_10_1007_s10555_012_9394_4 crossref_primary_10_1002_ijc_26268 crossref_primary_10_1186_1748_717X_7_48 crossref_primary_10_3109_09553000903232827 crossref_primary_10_3390_biom10060963 crossref_primary_10_1158_0008_5472_CAN_09_0657 crossref_primary_10_3389_fonc_2020_01260 crossref_primary_10_1007_s13277_015_4399_6 crossref_primary_10_1007_s11596_013_1153_4 crossref_primary_10_1016_j_critrevonc_2010_05_002 crossref_primary_10_1007_s11033_013_2849_z crossref_primary_10_1007_s11033_021_06607_3 crossref_primary_10_1158_0008_5472_CAN_10_1601 crossref_primary_10_3892_ol_2016_4590
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1158/0008-5472.CAN-08-0757
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1538-7445
ExternalDocumentID	18632646
Genre	Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NCI NIH HHS grantid: P01 CA 75138 – fundername: Medical Research Council grantid: G0700730 – fundername: NCI NIH HHS grantid: R01 CA 75830
GroupedDBID	--- -ET .55 18M 29B 2WC 34G 39C 3O- 53G 5GY 5RE 5VS 6J9 8WZ A6W AAFWJ AAJMC ABOCM ACGFO ACIWK ACPRK ADBBV ADCOW AENEX AETEA AFFNX AFHIN AFOSN AFRAH AFUMD AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW C1A CGR CS3 CUY CVF DIK DU5 EBS ECM EIF EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO MVM NPM OHT OK1 P0W P2P PQQKQ RCR RHI RNS SJN TR2 UDS VH1 W2D W8F WH7 WOQ X7M XJT YKV YZZ ZCG 7X8
ID	FETCH-LOGICAL-c3697-ea41cad6d3829c744c67f0b82c45b2207cf62d5110eab976a43c36ca7d075362
IEDL.DBID	7X8
ISSN	1538-7445
IngestDate	Thu Sep 04 18:31:26 EDT 2025 Mon Jul 21 05:36:43 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	14
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c3697-ea41cad6d3829c744c67f0b82c45b2207cf62d5110eab976a43c36ca7d075362
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://aacrjournals.org/cancerres/article-pdf/68/14/5915/2596355/5915.pdf
PMID	18632646
PQID	69319095
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_69319095 pubmed_primary_18632646
PublicationCentury	2000
PublicationDate	2008-Jul-15 20080715
PublicationDateYYYYMMDD	2008-07-15
PublicationDate_xml	– month: 07 year: 2008 text: 2008-Jul-15 day: 15
PublicationDecade	2000
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Cancer research (Chicago, Ill.)
PublicationTitleAlternate	Cancer Res
PublicationYear	2008
SSID	ssj0005105
Score	2.2971702
Snippet	Cell signaling initiated at the epidermal growth factor receptor (EGFR), RAS oncoproteins, or PI3K contributes to a common pathway that promotes tumor survival...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	5915
SubjectTerms	Cell Cycle Cell Line, Tumor DNA Damage Drug Screening Assays, Antitumor Enzyme Inhibitors - pharmacology Flow Cytometry - methods Furans - pharmacology G2 Phase Histones - metabolism Humans Phosphoinositide-3 Kinase Inhibitors Phosphorylation Pyridines - pharmacology Pyrimidines - antagonists & inhibitors Pyrimidines - pharmacology Radiation Tolerance Radiation-Sensitizing Agents - pharmacology
Title	Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity
URI	https://www.ncbi.nlm.nih.gov/pubmed/18632646 https://www.proquest.com/docview/69319095
Volume	68
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF6qFfHi-1Gfe_AaTbO72V0QpIjFgi099NBb2Vdo0Ca1D6H_3tkk1ZN48BLIkg1h8u3Ol8w3MwjdUieY0j79TGkbUAefO76qVSCjxDApjA5tUTL_lfd6YjiU_Rp6WOfCeFnlek8sNmqbG_-P_D6WABbgA4_Tj8D3jPKx1aqBxgaqEyAyHtN8-FMrnJUCxmJJc0pZlb_TZMKnL4iAUR7dPbV6hZyLM_47xyx8TXvvf0-5j3YrjolbJSgOUM1lh2i7W0XRj1BedMLEHdzvEPyWZuDIcJqNU13It7BeYWCFeLqapeDYVu_JEvxZ7k8nfuD72nwGN4ANlmCXjT145nixnMDoTNk0n3tlfNma4hgN2s-Dp5egarwQGBJLHjhFm0bZ2BIRSQO2MzFPQi0iQ5mOopCbJI4sULXQKQ18RlECE43iFuwIHvEEbWZ55s4QZi6RwnJhSSKolUw4ImyonCSxNkrJBrpZ23EEuPbBCpW5fDkfrS3ZQKflqxhNy_Ibo6aIgXPS-PzPuRdop5R38KDJLlE9gRXtrtCW-Vyk89l1ARc49vrdLzO-ypQ
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Class+I+PI3+kinase+inhibition+by+the+pyridinylfuranopyrimidine+inhibitor+PI-103+enhances+tumor+radiosensitivity&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Prevo%2C+Remko&rft.au=Deutsch%2C+Eric&rft.au=Sampson%2C+Oliver&rft.au=Diplexcito%2C+Julie&rft.date=2008-07-15&rft.eissn=1538-7445&rft.volume=68&rft.issue=14&rft.spage=5915&rft_id=info:doi/10.1158%2F0008-5472.CAN-08-0757&rft_id=info%3Apmid%2F18632646&rft_id=info%3Apmid%2F18632646&rft.externalDocID=18632646
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-7445&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-7445&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-7445&client=summon